Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leigh MacConell

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Cardiovascular Diabetology|February 4, 2015
Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetesLawrence Blonde, Richard Pencek, Leigh MacConell
Diabetes Care|July 21, 2016
Efficacy and Safety of Multiple Doses of Exenatide Once-Monthly Suspension in Patients With Type 2 Diabetes: A Phase II Randomized Clinical TrialCarol H Wysham, Leigh MacConell, Elise Hardy
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|March 1, 2012
Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trialsLeigh Macconell, Carl Brown, Kate Gurney, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|June 10, 2015
Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patientsLeigh MacConell, Kate Gurney, Jaret Malloy, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|January 30, 2013
Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 yearsLeigh Macconell, Richard Pencek, Yan Li, et al.
Advances in Therapy|August 16, 2017
Assessment of Pharmacokinetic Interactions Between Obeticholic Acid and Caffeine, Midazolam, Warfarin, Dextromethorphan, Omeprazole, Rosuvastatin, and Digoxin in Phase 1 Studies in Healthy SubjectsJeffrey E Edwards, Lise Eliot, Andrew Parkinson, et al.
Diabetes Technology & Therapeutics|July 15, 2011
Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetesMary Beth DeYoung, Leigh MacConell, Viren Sarin, et al.
Alimentary Pharmacology & Therapeutics|February 13, 2025
Challenges in Histological Endpoints for MASH Therapies: An Exercise in Statistical ModellingAmrik Shah, Leigh MacConell, Alexander Liberman, et al.
Lancet (London, England)|September 6, 2020
Clinical endpoints are necessary in the interim analysis of REGENERATE - Authors' replyVlad Ratziu, Zobair M Younossi, Jason A Campagna, et al.
Clinical Therapeutics|May 22, 2012
Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in HungaryTibor Iványi, József Fövényi, Péter Faludi, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Cardiovascular Diabetology|February 4, 2015
Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetesLawrence Blonde, Richard Pencek, Leigh MacConell
Diabetes Care|July 21, 2016
Efficacy and Safety of Multiple Doses of Exenatide Once-Monthly Suspension in Patients With Type 2 Diabetes: A Phase II Randomized Clinical TrialCarol H Wysham, Leigh MacConell, Elise Hardy
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|March 1, 2012
Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trialsLeigh Macconell, Carl Brown, Kate Gurney, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|June 10, 2015
Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patientsLeigh MacConell, Kate Gurney, Jaret Malloy, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|January 30, 2013
Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 yearsLeigh Macconell, Richard Pencek, Yan Li, et al.
Advances in Therapy|August 16, 2017
Assessment of Pharmacokinetic Interactions Between Obeticholic Acid and Caffeine, Midazolam, Warfarin, Dextromethorphan, Omeprazole, Rosuvastatin, and Digoxin in Phase 1 Studies in Healthy SubjectsJeffrey E Edwards, Lise Eliot, Andrew Parkinson, et al.
Diabetes Technology & Therapeutics|July 15, 2011
Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetesMary Beth DeYoung, Leigh MacConell, Viren Sarin, et al.
Alimentary Pharmacology & Therapeutics|February 13, 2025
Challenges in Histological Endpoints for MASH Therapies: An Exercise in Statistical ModellingAmrik Shah, Leigh MacConell, Alexander Liberman, et al.
Lancet (London, England)|September 6, 2020
Clinical endpoints are necessary in the interim analysis of REGENERATE - Authors' replyVlad Ratziu, Zobair M Younossi, Jason A Campagna, et al.
Clinical Therapeutics|May 22, 2012
Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in HungaryTibor Iványi, József Fövényi, Péter Faludi, et al.
Pageof 4